We thank Sharon Maxwell, Westlakes Scientific Consulting, for data management; Alastair Sword, Pharmapart UK Ltd, for statistical analysis; and Anne MacKenzie of Kendle UK, for project management. Packaging and provision of drug and placebo capsules were performed by PCI Clinical Services. Adverse event monitoring was performed by ClinTrials Research Ltd, Glasgow, Scotland. The patients were seen by the following 2 groups of family practitioners in the United Kingdom with a specialist interest in depression and in clinical trials of antidepressant drugs: MGB Group: George Beaumont, MB, ChB, and Max Gringras, MB, ChB, Poynton, England; and W. R. C. Aitchison, MB, ChB, and G. I. McLaren, Bridge of Weir, Scotland. QED Group: S. Connolly, MB, ChB, Hamilton, Scotland; J. Thompson, MB, ChB, P. D. Flanigan, MB, ChB, and D. Kilgour, MB, ChB, Coatridge, Scotland; and W. Scullion, MB, ChB, Airdrie, Scotland.